A Double-Masked, Randomized, Placebo-Controlled Study of Trabecular Outflow Facility Following Treatment With Netarsudil Ophthalmic Solution 0.02% (AR-13324) in Subjects With Elevated Intraocular Pressure
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2018
At a glance
- Drugs Netarsudil (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Aerie Pharmaceuticals
- 12 Apr 2018 Planned End Date changed from 1 May 2018 to 1 Jul 2018.
- 12 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 May 2018.
- 01 Dec 2017 Status changed from not yet recruiting to recruiting.